Open House Drug Discount Agreement Posaconazole
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Posaconazol, ATC J02AC04
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
30 / 100
Risk factors
No contract value or volume is disclosed. Potential revenue is unknown.
The open-house agreement automatically suspends if a competitive discount contract for the same substance comes into ef...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until May 2027
- Conclusion of non-exclusive discount agreements for Posaconazole (ATC J02AC04) with AOK Bayern.
- Pharmaceutical companies must supply Posaconazole products and adhere to the discount terms set in the contract.
Show full summary
This is an open-house model (non-competitive) for non-exclusive drug discount agreements for Posaconazole (ATC J02AC04) by AOK Bayern. Any eligible pharmaceutical company can join at any time during the contract period. The contract runs from 01.06.2025 to 31.05.2027. No estimated value is provided. Eligibility requires a signed self-declaration of reliability. Submission can be in paper form (2 copies) or electronically with a qualified electronic signature via the DTVP portal. The notice explicitly states this is not a public procurement procedure under EU procurement law.
Risks
No contract value or volume is disclosed. Potential revenue is unknown.
The open-house agreement automatically suspends if a competitive discount contract for the same substance comes into ef...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Only pharmaceutical companies are eligible to participate.
Administrative
- Must submit a signed self-declaration of reliability (downloaded from the procurement portal).
- The signed contract and annex 'Specification of the contract drugs' must be submitted along with the self-declaration.
Award Criteria
Lot 1
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open House Drug Discount Agreement Posaconazole
Non-exclusive discount agreements for the active substance Posaconazole (ATC J02AC04). The contract is open to all interested pharmaceutical companies that meet the eligibility criteria. Contracts can be concluded at any time up to 05.04.2027, with earliest start 01.06.2025 and all contracts ending 31.05.2027.
Location
Duration
Category
Award Criteria
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Posaconazol, ATC J02AC04
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Procurement Details
- Publication date
- 15 Apr 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 248660-2025
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
30 / 100
Risk factors
No contract value or volume is disclosed. Potential revenue is unknown.
The open-house agreement automatically suspends if a competitive discount contract for the same substance comes into ef...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications